CH Biomedical focuses on the research and development of the world’s state-of-the art ventricular assist device (VAD), promotes the commercialization of the VADs, and brings benefits to patients with end-stage heart failure.
On August 7, People’s Daily published an article titled Domestic Fully Magnetically Levitated VAD Serving Patients, commending CH Biomedical for breaking the international technological monopoly for developing a domestically produced, fully magnetically levitated VAD with independent intellectual property rights. The device is currently available in nearly 40 hospitals across China, enabling over 140 patients with advanced heart failure to embark on a “new life”.
Recently, at the 2022 China Medical Development Conference—widely regarded as the country’s premier medical forum—the Chinese Academy of Medical Sciences (CAMS) released two lists: China’s Major Medical Achievements of the 21st Century and China’s Important Medical Advancements in 2021. As a global innovator in the field of Ventricular Assist Devices (VADs), CH Biomedical’s independently developed CH-VAD (NMPA (A) 20213120987) was included in China’s Important Medical Advancements in 2021.
On November 24th 2021, the implantable CH-VAD® left ventricular assist system (CH-VAD® LVAS) of CH Biomedical was approved by the National Medical Products Administration (NMPA) for marketing (Registration No.: GXZZ 20213120987). CH-VAD LVAS was developed independently by CH Biomedical, it is the first Left Ventricular Assist Device (LVAD) with complete independent intellectual property rights approved by NMPA in China, and the first full magnetic levitation LVAD approved by NMPA.
